MV Capital Management Inc. Has $210,000 Holdings in Pfizer Inc. $PFE

MV Capital Management Inc. grew its position in Pfizer Inc. (NYSE:PFE) by 76.5% during the second quarter, HoldingsChannel reports. The firm owned 8,656 shares of the biopharmaceutical company’s stock after buying an additional 3,753 shares during the period. MV Capital Management Inc.’s holdings in Pfizer were worth $210,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of PFE. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer in the 1st quarter worth about $27,000. Curio Wealth LLC grew its holdings in Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares during the period. Bayforest Capital Ltd bought a new stake in Pfizer in the first quarter valued at $28,000. Harbor Asset Planning Inc. acquired a new position in shares of Pfizer during the second quarter valued at about $29,000. Finally, WPG Advisers LLC bought a new position in shares of Pfizer during the 1st quarter worth about $35,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of a number of research reports. Bank of America upped their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. UBS Group reaffirmed a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st. The Goldman Sachs Group reissued a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a research report on Wednesday, November 5th. Citigroup upped their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $28.18.

Pfizer Price Performance

PFE opened at $25.84 on Thursday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The firm’s fifty day moving average price is $24.77 and its two-hundred day moving average price is $24.42. The company has a market capitalization of $146.92 billion, a price-to-earnings ratio of 13.75, a P/E/G ratio of 0.81 and a beta of 0.54. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.